HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach.

AbstractBACKGROUND:
A brief course of chemotherapy followed by radiation therapy was considered the best treatment for localized high-grade Non-Hodgkin's Lymphoma (NHL). The purpose of this study was to determine the efficacy and feasibility of a brief-course of anthracycline-based chemotherapy (CHOP) and consolidation radiation therapy (CRT) in a series of 57 consecutive patients with stage I-IE intermediate-high grade NHL.
PATIENTS AND METHODS:
Between January 1990 and December 1998, 57 consecutive patients, stage I=31 (55%) and stage IE=26 (45%), were treated with 3 cycles of CHOP regimen. Forty-four (77%) received a CRT and thirteen (23%) with primitive gastric and splenic NHL underwent radical surgery. Multivariate analysis was performed to evaluate age, lactate dehydrogenase (LDH), bulky, nodal versus extranodal localization, as prognostic factors of locoregional control and survival.
RESULTS:
After a median follow-up of 84 months (range 4-128 months) the 5-year overall survival (OS), disease-free survival (DFS) and event-free survival (EFS) rates were 88%, 87.5% and 84%, respectively. Risk factor analysis revealed that the LDH value was the most important adverse prognostic factor for OS and EFS. No differences were found regarding the age and or extranodal localization. The 5-year OS, DFS and EFS was 100% in thirteen patients with primitive gastric or splenic NHL treated with a radical surgical approach followed by chemotherapy without CRT.
CONCLUSION:
We confirm the efficacy and feasibility of a brief course of CHOP chemotherapy followed by CRT in localized I-IE intermediate-high grade NHL without adverse prognostic factors. Randomized studies are warranted in order to define the dose and the target volume of CRT (involved field or extended field) in this setting of patients.
AuthorsV De Sanctis, M Martelli, A P Anticoli, R Caronna, P Chirletti, M Giovannini, M Santarelli, R M Enrici, F Mandelli
JournalAnticancer research (Anticancer Res) 2001 Nov-Dec Vol. 21 Issue 6A Pg. 4169-72 ISSN: 0250-7005 [Print] Greece
PMID11911313 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Combined Modality Therapy
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Humans
  • Lymphoma, Non-Hodgkin (drug therapy, pathology, radiotherapy)
  • Middle Aged
  • Neoplasm Staging
  • Prednisone (administration & dosage)
  • Prospective Studies
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: